Smoldering Multiple Myeloma — Trials

Smoldering Multiple Myeloma — Trials · CancerIndex

Clinical trials

Registered studies

85 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 34
Recruiting: 13
Ph III recruiting: 1
Growth YoY: —
Industry share: 9%
Top sponsor: Dana-Farber Cancer Institute
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (11)

clinicaltrialsPublishedShowing 1–3 of 3 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06768489	A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma	recruiting	Phase 1	276	Janssen Research & Development, LLCINDUSTRY	5	Sep 25, 2026	clinicaltrials
NCT02886065	A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM	active not recruiting	Phase 1	19	Massachusetts General HospitalOTHER